J&J cuts Nizoral to focus on core lines
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Johnson & Johnson (J&J) is offloading the rights to the Nizoral dandruff treatment in three separate deals as part of its strategy to divest non-core assets and focus on its larger Consumer brands.